These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 1622122)

  • 1. Increasing peak levels of vinblastine given in repeated divided doses.
    Van Belle SJ; de Smet MC; De Mey JE; De Neve W; Massart DL; Storme G
    Anticancer Res; 1992; 12(3):655-9. PubMed ID: 1622122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.
    Trump DL; Ravdin PM; Borden EC; Magers CF; Whisnant JK
    J Biol Response Mod; 1990 Feb; 9(1):108-11. PubMed ID: 2319258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of divided-dose vinblastine in advanced malignancy.
    Young JA; Westlake D; Schnetzer GW; Keller AM; Sexauer JM; Newcomer LN
    Cancer Treat Rep; 1985 Jun; 69(6):607-10. PubMed ID: 4016767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
    de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
    J Hypertens; 1998 Sep; 16(9):1357-69. PubMed ID: 9746123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
    de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
    J Hypertens; 1998 Nov; 16(11):1357-69. PubMed ID: 9856375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
    van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
    Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
    Weiss GR; Poggesi I; Rocchetti M; DeMaria D; Mooneyham T; Reilly D; Vitek LV; Whaley F; Patricia E; Von Hoff DD; O'Dwyer P
    Clin Cancer Res; 1998 Jan; 4(1):53-9. PubMed ID: 9516952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL.
    Nuessler V; Scheulen ME; Oberneder R; Kriegmair M; Goebel KJ; Rathgeb F; Wurst W; Zech K; Wilmanns W
    Eur J Med Res; 1997 Feb; 2(2):55-61. PubMed ID: 9085015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.
    Schilcher RB; Haas CD; Samson MK; Young JD; Baker LH
    Cancer Res; 1986 Jun; 46(6):3147-51. PubMed ID: 3698029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.